An actor with vitiligo stars in Incyte's first DTC work for Opzelura to treat the autoimmune skin condition.
March 14, 2023 12:59 PM EDTUpdated 04:16 PM
Pharma
Marketing

In­cyte adds first Opzelu­ra brand TV com­mer­cial, and a fa­mous voice, to its vi­tili­go ef­forts

Beth Snyder Bulik

Senior Editor

A well-known celebri­ty voice is ush­er­ing in In­cyte’s lat­est cam­paign around the skin de­pig­men­ta­tion con­di­tion vi­tili­go. Ac­tor Mor­gan Free­man doesn’t ap­pear in In­cyte’s first brand­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Bio­phar­ma be­gins to con­tem­plate an RFK Jr.-in­flu­enced FDA if Trump wins

Pfiz­er shares new de­tails on obe­si­ty pipeline, hints at ‘oth­er op­por­tu­ni­ties’

GSK buys au­toim­mune T cell en­gager for $300M up­front from Chim­a­gen

No­var­tis takes $800M Mor­phoSys write­down mere months af­ter clos­ing ac­qui­si­tion

No­var­tis high­lights over­all M&A track record fol­low­ing Mor­phoSys im­pair­ment

Fol­low­ing March in­spec­tion, No­vo Nordisk's semaglu­tide man­u­fac­tur­ing fa­cil­i­ty cit­ed by FDA

A service from the Financial Times